Insulin aspart
| Clinical data | |
|---|---|
| Trade names | Novolog, Novorapid, Fiasp, others |
| Biosimilars | insulin aspart-szjj,[1] Kirsty,[2] Merilog,[1] Merilog Solostar,[1] Trurapi,[3] Truvelog[4] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605013 |
| License data | |
| Pregnancy category | |
| Routes of administration | Subcutaneous, intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | 15 minutes |
| Duration of action | 3–5 hours |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C256H381N65O79S6 |
| Molar mass | 5825.60 g·mol−1 |
| (what is this?) (verify) | |
Insulin aspart, sold under the brand name Novolog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes.[18] It is generally used by injection under the skin (into the abdomen, buttocks, thighs, or upper arms) but may also be used by injection into a vein.[18] Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours.[18] Generally a longer-acting insulin like insulin NPH is also needed.[18][19]
Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection.[18] Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain and swelling of hands and feet.[1][20] Other serious side effects may include low blood potassium (hypokalemia),[18] low blood sugar (hypoglycemia),[1][20] and severe allergic reactions.[1][20] Use in pregnancy and breastfeeding is generally safe.[5] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[18] It is a manufactured form of human insulin; where a single amino acid has been changed, specifically a proline with an aspartic acid at the B28 position.[21]
Insulin aspart was approved for medical use in the United States in 2000.[18] In 2022, it was the 76th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[22][23] Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome.[24] This yeast then makes the insulin, which is harvested from the bioreactor.[25]
- ^ a b c d e f "Merilog- insulin aspart-szjj injection, solution". DailyMed. 19 February 2025. Retrieved 3 March 2025.
- ^ a b Cite error: The named reference
Kirsty EPARwas invoked but never defined (see the help page). - ^ "Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
- ^ a b c Cite error: The named reference
Truvelog APMDSwas invoked but never defined (see the help page). - ^ a b "Insulin aspart Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ a b "Australian Public Assessment Report for Insulin aspart" (PDF). Therapeutic Goods Administration (TGA). March 2021. Archived from the original (PDF) on 24 June 2021.
- ^ "Australian Public Assessment Report for Insulin aspart (rys)" (PDF). Therapeutic Goods Administration (TGA). August 2021. Archived from the original (PDF) on 5 February 2022.
- ^ Cite error: The named reference
Truvelog Solostar ARTGwas invoked but never defined (see the help page). - ^ "Regulatory Decision Summary - Fiasp". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
- ^ "Regulatory Decision Summary - Trurapi". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
- ^ "Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ Cite error: The named reference
NovoRapid SmPCwas invoked but never defined (see the help page). - ^ "Fiasp- insulin aspart injection injection, solution". DailyMed. 19 December 2019. Archived from the original on 13 November 2020. Retrieved 12 November 2020.
- ^ "Novolog- insulin aspart injection, solution Insulin Diluting Medium For Novolog- water injection injection, solution". DailyMed. 15 November 2019. Archived from the original on 12 November 2020. Retrieved 12 November 2020.
- ^ "Novolog Mix 70/30- insulin aspart injection, suspension". DailyMed. 15 November 2019. Archived from the original on 29 September 2020. Retrieved 12 November 2020.
- ^ Cite error: The named reference
NovoMix EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Truvelog Mix 30 EPARwas invoked but never defined (see the help page). - ^ a b c d e f g h "Insulin Aspart Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "FDA Approves First Insulin Aspart Biosimilar". Center for Biosimilars. 17 February 2025. Retrieved 19 February 2025.
- ^ a b c Cite error: The named reference
FDA PR 20250214was invoked but never defined (see the help page). - ^ Turner JR (2010). New Drug Development: An Introduction to Clinical Trials: Second Edition. Springer Science & Business Media. p. 32. ISBN 9781441964182. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Insulin Aspart Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
- ^ Banga AK (2005). Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Second Edition. CRC Press. p. 13. ISBN 9781420039832. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
- ^ Schmid RD, Schmidt-Dannert C (2016). Biotechnology: An Illustrated Primer. John Wiley & Sons. p. 222. ISBN 9783527677566. Archived from the original on 20 April 2021. Retrieved 11 September 2020.